On January 30, 2024 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, reported that Dr. Oren Gilad, President and CEO, will deliver a presentation at the 7th DDR Inhibitors Summit, to take place January 30 to February 1, 2024 in Boston, MA (Press release, Aprea, JAN 30, 2024, View Source [SID1234639702]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to have the opportunity to present at the DDR Inhibitors Summit," said Dr. Oren Gilad. "DDR has been identified as an important pathway for treating cancer, and there is considerable ongoing progress in the development of potential new therapeutics. Aprea is positioned at the forefront of this wave of innovation, and we look forward to providing an update to the oncology community at this year’s summit."
Presentation Details
Title: Prioritizing Patient Selection for Combination Studies to Optimize Treatments
Date/ Time: 9am ET, Thursday February 1, 2024
Location: The Colonnade, 120 Huntington Ave, Boston, MA
Dr. Gilad’s presentation will be followed by a roundtable panel discussion "What Defines Clinical Success for Current & Next-Generation DDR Inhibitors?"
Brian Wiley, SVP of Corporate Strategy at Aprea, will also be attending the Summit and will be available for 1on1 meetings.